NorthX Biologics’ investor and CEO of Flerie, Ted Fjällman made a guest appearance in a recent episode of Värdeskaparna, a podcast taking the audience behind the scenes in the private equity world.
During the podcast, Ted delves into the biotech industry’s current trends and future directions, sharing his valuable insights and experiences.
Click the link below to listen (in Swedish):
Värdeskaparna with Ted Fjällman
NorthX Biologics is a CDMO and Innovation Hub in Advanced Biologics, with +30 years of GMP production experience. The team provides process development and GMP manufacturing services with expertise in plasmid DNA, mRNA, proteins, cells and other advanced biologics. Headquartered in the heart of Sweden, the team serves customers worldwide and in 2021 was recognized as a national innovation hub for advanced therapeutics and vaccines. NorthX Biologics has the ambition to become a leading cell and gene therapy manufacturer and partner of choice for innovative drug development companies.
For more news, follow us on LinkedIn
The study of proteins is transforming our understanding of human biology and disease, enabling breakthroughs in diagnostics, drug development, and advanced therapies. In this article, Mathias Uhlén, Professor of Microbiology ...
Janet Hoogstraate, the CEO of NorthX Biologics, recently appeared in an episode of Q-podden, a podcast on manufacturing, quality and corporate culture in life science. Janet discusses the latest trends and ...
On behalf of the Swedish Ministry for Foreign Affairs and Gavi, the Global Vaccine Alliance, NorthX Biologics’ CEO Janet Hoogstraate participated in an important roundtable on “Leveraging Technology and Innovation to Ensure Every ...